| Project Acronym | EURIPRED |
|---|---|
| Funding Program | FP7 |
| Budget | €8,484,910 |
| Coordinator | NIBSC (UK) |
| Website | http://www.euripred.eu |
| Starting-End Date | 2013-2017 |
| EATRIS participating institutions | ISS (IT); BPRC (NL); HZI (DE) |
| EATRIS WP leadership | WP2 Networking |
| EATRIS budget | 411,268 € |
| Tags | EU project, fp7, Infectious diseases, Research infrastructure, Vaccines |
EURIPRED in one page
Find out more about the EURIPRED consortium and the objectives of the project!
EURIPRED (European Research Infrastructures for Poverty Related Diseases) is a collaborative infrastructure programme with the objective to reinforce the knowledge infrastructure across diseases. The ultimate aim is to speed the development of new tools (vaccines, drugs, microbicides) to combat Tuberculosis, HIV, Malaria, Hepatitis B and Hepatitis C. EURIPRED is co-funded with € 8.5 million by the European Commission. Scientists from 17 research partners in 10 countries collaborate in this programme.
EURIPRED started in November 2013, is a 4-year project and has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No 312661.
Tuberculosis Vaccine development
Last month in J Immunol Methods, Tanner et al established a standardised operating procedure (SOP) for the use of the Mycobacterial growth inhibition assays in TB vaccine development.
